# CYH33

Source: https://onco.cc/drugs/cyh33/  
OnCo record `cyh33` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CYH33 is a small-molecule inhibitor from Haihe Biopharma Co., Ltd., in registered phase 2 trials for ovarian cancer.

## Summary

CYH33 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Haihe Biopharma Co., Ltd., in ovarian cancer. Described in the registry record as a small-molecule inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: CYH33
- Modality: Small-molecule inhibitor
- Mechanism: Described in the registry record as a small-molecule inhibitor; the trial entries below carry the sponsor's wording.

## Sources

- ClinicalTrials.gov: trials of CYH33: https://clinicaltrials.gov/search?intr=CYH33

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- companies: [Haihe Biopharma](https://onco.cc/companies/haihe-biopharma/)
- trials: [A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma](https://onco.cc/trials/nct05043922/)

---
JSON: https://onco.cc/api/v1/entities/cyh33.json